Mealey's (August 30, 2019, 9:39 AM EDT) -- WASHINGTON, D.C. — In an Aug. 29 order, a divided Federal Circuit U.S. Court of Appeals panel found that it is barred from reviewing a discretionary denial by the Patent Trial and Appeal Board (PTAB) of institution of inter partes review (IPR), one year after the appellate court remanded the dispute to the board over the objections of the U.S. Patent and Trademark Office (PTO) (BioDelivery Sciences International Inc. v. Aquestive Therapeutics Inc., Nos. 2019-1643, -1644, -1645, Fed. Cir., 2019 U.S. App. LEXIS 26281)....